Current methods for detecting early signs of diseases such as Alzheimer's, Parkinson's, and cardiovascular issues often rely on late-stage symptom identification, leading to irreversible damage and limited treatment effectiveness. Traditional diagnostic approaches can be invasive, costly, and may not provide the detailed insights needed for early intervention.

OptoIntel leverages hyperspectral imaging (HSI) and machine learning to analyze retinal biomarkers, enabling early detection of neurodegenerative, cardiovascular, and other systemic diseases. Their wide-field fundus camera captures retinal data across hundreds of spectral bands in under a second, generating detailed spectral fingerprints. AI algorithms then analyze these fingerprints to identify subtle disease indicators at the cellular level, often before symptoms manifest. This non-invasive, cost-effective approach facilitates proactive management of risk factors and eligibility for disease-modifying therapies, improving patient outcomes by enabling intervention when damage is minimal.

Wide-field hyperspectral fundus camera captures retinal data across hundreds of spectral bands in less than one second.

AI-powered analysis of spectral fingerprints identifies disease-corresponding retinal biomarkers.

Non-invasive retinal imaging eliminates the need for pupil dilation.

High-resolution imaging discerns changes at the cellular level.

Operator-independent automation aligns the pupil and retina within seconds.

Scalable platform operates with minimal overhead costs.

OptoIntel targets healthcare providers, pharmaceutical companies, and research institutions focused on early disease detection, patient screening, and drug development for neurodegenerative, cardiovascular, and other systemic diseases.